HealthEquity, Inc. (NASDAQ:HQY - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $88.47 and last traded at $87.15, with a volume of 86966 shares changing hands. The stock had previously closed at $85.87.
Analysts Set New Price Targets
HQY has been the topic of a number of recent analyst reports. Barrington Research reissued an "outperform" rating and set a $105.00 price target on shares of HealthEquity in a research report on Friday, September 20th. Deutsche Bank Aktiengesellschaft raised their price target on HealthEquity from $102.00 to $103.00 and gave the company a "buy" rating in a report on Wednesday, September 4th. Royal Bank of Canada reiterated an "outperform" rating and issued a $92.00 price objective on shares of HealthEquity in a report on Wednesday, September 4th. JMP Securities restated a "market outperform" rating and set a $105.00 target price on shares of HealthEquity in a research note on Wednesday, September 4th. Finally, Wells Fargo & Company increased their price target on shares of HealthEquity from $107.00 to $110.00 and gave the company an "overweight" rating in a report on Thursday, June 20th. Twelve equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $103.83.
Read Our Latest Stock Report on HQY
HealthEquity Trading Up 2.5 %
The stock has a market capitalization of $7.66 billion, a P/E ratio of 95.65, a P/E/G ratio of 1.31 and a beta of 0.52. The company has a current ratio of 4.10, a quick ratio of 4.10 and a debt-to-equity ratio of 0.51. The business has a 50-day moving average price of $78.42 and a two-hundred day moving average price of $79.43.
HealthEquity (NASDAQ:HQY - Get Free Report) last announced its quarterly earnings data on Tuesday, September 3rd. The company reported $0.66 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.50 by $0.16. HealthEquity had a net margin of 9.61% and a return on equity of 9.01%. The firm had revenue of $299.93 million for the quarter, compared to the consensus estimate of $284.48 million. On average, analysts expect that HealthEquity, Inc. will post 2.27 EPS for the current fiscal year.
Insider Activity at HealthEquity
In other HealthEquity news, Director Frank Corvino sold 1,247 shares of the firm's stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $80.26, for a total value of $100,084.22. Following the sale, the director now owns 4,823 shares of the company's stock, valued at approximately $387,093.98. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, Director Frank Corvino sold 1,247 shares of the stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $80.26, for a total value of $100,084.22. Following the completion of the transaction, the director now owns 4,823 shares of the company's stock, valued at approximately $387,093.98. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Robert W. Selander sold 8,250 shares of HealthEquity stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $82.98, for a total transaction of $684,585.00. Following the sale, the director now directly owns 54,719 shares in the company, valued at $4,540,582.62. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 44,497 shares of company stock valued at $3,579,769 over the last three months. 2.20% of the stock is owned by insiders.
Institutional Trading of HealthEquity
Hedge funds have recently made changes to their positions in the company. Rise Advisors LLC bought a new position in HealthEquity in the 1st quarter valued at approximately $28,000. International Assets Investment Management LLC bought a new stake in shares of HealthEquity in the second quarter worth $35,000. Paladin Wealth LLC bought a new position in HealthEquity during the 3rd quarter worth $39,000. Fidelis Capital Partners LLC bought a new position in HealthEquity during the 1st quarter worth $42,000. Finally, GAMMA Investing LLC lifted its holdings in HealthEquity by 114.8% during the 2nd quarter. GAMMA Investing LLC now owns 595 shares of the company's stock worth $51,000 after buying an additional 318 shares during the period. 99.55% of the stock is owned by institutional investors and hedge funds.
About HealthEquity
(
Get Free Report)
HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Further Reading
Before you consider HealthEquity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HealthEquity wasn't on the list.
While HealthEquity currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
